Precigen (NASDAQ:PGEN) Releases Earnings Results

Precigen (NASDAQ:PGEN) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.09, FiscalAI reports. Precigen had a negative return on equity of 2,313.82% and a negative net margin of 2,588.21%.The business had revenue of $4.57 million during the quarter, compared to analysts’ expectations of $8.29 million.

Here are the key takeaways from Precigen’s conference call:

• Company expects Q1 2026 revenue to exceed $18 million, up from $3.4 million in Q4 after a November launch, signaling rapid commercial uptake of PAPZIMEOS.
• Precigen ended 2025 with $100.4 million in cash and investments and expects those funds plus PAPZIMEOS sales to fund operations through cash‑flow breakeven by end of 2026.
• FY2025 net loss was $429.6 million, driven largely by $318.5 million of one‑time non‑cash preferred stock/warrant items that management says will not recur; R&D declined due to pipeline prioritization while SG&A rose ≈$28.8M for the commercial launch.
• Commercial traction is strong with over 300 patients in the company hub, payer coverage expanded to ~215 million lives (~90% of insured U.S. lives), and a permanent J‑code effective April 1 to streamline reimbursement.
• Pipeline and expansion plans include a pediatric RRP trial targeted for Q4 2026, an EMA MAA under review for Europe, and continued development of PRGN‑2009 in Phase II combos for HPV‑related cancers, representing upside that remains subject to clinical and regulatory risk.

Precigen Stock Up 25.3%

Shares of PGEN opened at $3.89 on Friday. The firm has a market cap of $1.37 billion, a P/E ratio of -2.90 and a beta of 1.10. Precigen has a 12 month low of $1.11 and a 12 month high of $5.47. The stock’s 50 day moving average is $4.10 and its two-hundred day moving average is $3.98. The company has a current ratio of 4.04, a quick ratio of 3.95 and a debt-to-equity ratio of 2.22.

Key Headlines Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: PAPZIMEOS commercial momentum: Precigen reported PAPZIMEOS generated $3.4M in net product revenue in Q4 (partial quarter) and said demand picked up sharply into Q1; company has $100.4M in cash to fund operations toward a 2026 cash-flow breakeven target. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Company guidance and payer progress: Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates with broad U.S. payer coverage; CMS assigned a permanent J‑code (J3404) effective Apr 1, which should streamline reimbursement. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates with broad U.S. payer coverage
• Positive Sentiment: Analyst upgrades and higher targets: Multiple firms raised price targets and ratings after the results (HC Wainwright to $10 buy; Citizens JMP to $9 market outperform), reflecting expectations for meaningful upside as the commercial rollout scales. These Analysts Boost Their Forecasts On Precigen Following Q4 Results
• Positive Sentiment: Bull thesis and modeled upside: A recent deep-dive bullish note highlights PAPZIMEOS’s blockbuster potential, models Q1 run-rate and payer traction, and produces a probability-weighted fair value (~$6.13–$7.01 per share) above current levels. Precigen: The Best Potential Blockbuster You’ve Never Heard Of (Your ENT Has)
• Neutral Sentiment: Earnings call and transcripts available: Management held its full-year 2025 call and provided operational color on commercial expansion and an open‑label redosing study; transcripts and call highlights are published. Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 revenue missed estimates: Reported EPS beat slightly (smaller loss) but Q4 revenue was $4.57M vs. consensus ~$8.29M; the company still shows deep negative margins and high leverage metrics, which are risks until commercial revenues scale. Precigen (PGEN) Q4 2025 Earnings / MarketBeat
• Negative Sentiment: Valuation and momentum caution: Coverage pieces note PGEN’s ~145% one‑year run, and some investors may view current gains as late-stage momentum, raising near-term valuation risk if launch cadence or reimbursement lags expectations. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?

Wall Street Analysts Forecast Growth

Several research firms have commented on PGEN. HC Wainwright upped their price objective on Precigen from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday. Citizens Jmp lifted their target price on shares of Precigen from $8.00 to $9.00 and gave the company a “market outperform” rating in a report on Thursday. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a report on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $9.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Precigen in the third quarter valued at about $39,000. Russell Investments Group Ltd. purchased a new stake in Precigen during the 3rd quarter valued at about $41,000. Mason Investment Advisory Services Inc. purchased a new stake in Precigen during the 4th quarter valued at about $42,000. Abel Hall LLC acquired a new stake in Precigen in the 4th quarter valued at about $44,000. Finally, NewEdge Advisors LLC acquired a new stake in Precigen in the 4th quarter valued at about $45,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.